Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual MeetingCompany to host Key Opinion Leader webinar on September 12 at 2:00 pm CT/3:00 pm ETLYON, France and CAMBRIDGE, Mass., Sept. 01,.
Company to host Key Opinion Leader webinar on September 12 at 2:00 pm CT/3:00 pm ETLYON, France and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) Amolyt Pharma, a global company specialized in developing